Comparative Pharmacology
Head-to-head clinical analysis: PLENAXIS versus SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLENAXIS versus SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE.
PLENAXIS vs SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective androgen receptor modulator (SARM); binds to androgen receptors with high affinity, activating anabolic signaling pathways in muscle and bone with reduced androgenic effects on prostate and skin.
Spironolactone is a competitive aldosterone antagonist that inhibits sodium reabsorption in the cortical collecting tubule, increasing potassium retention. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule, enhancing diuresis and reducing blood pressure.
Initial: 10 mg orally once daily, titrated to blood pressure and heart rate response; maintenance: 20-80 mg daily in 1-2 divided doses.
Oral, 1 tablet (spironolactone 25 mg / hydrochlorothiazide 25 mg) once daily; may increase to 2 tablets per day if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours in healthy adults; clinically significant accumulation occurs in renal impairment (CrCl <30 mL/min) with half-life prolonged to 40-60 hours.
Spironolactone: Terminal half-life of active metabolites ~12-15 h (canrenone 16-24 h). Hydrochlorothiazide: 6-15 h (renal impairment prolongs).
Renal: 70% as unchanged drug; fecal: 10% as metabolites; biliary: 5% as unchanged drug and metabolites.
Spironolactone: Renal (80% as active metabolites, 10% as canrenone); Fecal (minor). Hydrochlorothiazide: Renal (≥95% unchanged).
Category C
Category D/X
Aldosterone Antagonist
Aldosterone Antagonist